News
LICTOR, a new powerful tool to prevent systemic light-chain amyloidosis
Systemic light-chain amyloidosis (AL) is the most common form of a group of diseases associated with protein misfolding, leading to deposition of insoluble structures in different organs. Due to the...
New paper from the González’s lab
A paper from the González’s lab studies how to modify the innate immune response to improve the adaptive immunity against a potential HIV vaccine. To study this mechanism, we have employed the revolu...
A single new weapon against multiple viruses transmitted by ticks
The bite of a tick can transmit Tick-Borne Encephalitis Virus (TBEV), which can cause brain infection, hospitalisation and long term neurologic problems. TBEV is only one among half a dozen vir...
Prestigious professorship awarded at the Institute of Oncology Research in Bellinzona
Stiftung Experimentelle Biomedizin has awarded Dr Arianna Calcinotto, Group Leader at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana) the Peter Hans...
The IRB joins international network for the study of emerging infectious diseases
The IRB announces it has joined the United World Antiviral Research Network (UWARN), the organisation that brings together researchers from leading institutions in several countries around the globe t...
IOR study reveals how breast cancer therapy may be effective against COVID-19
A study conducted by the Institute of Oncology Research (IOR, affiliated to USI) based on data obtained from the Veneto Tumor Registry (Italy) has observed a lower risk of developing the coronavirus d...
Why Specific Genetic Alterations Matter in Prostate Cancer
A given substance may be fundamental for life or may serve as a poison. All depends on the specific dose. At first glance, this somewhat paradoxical principle in medicine was first coined by the Swiss...
Circulating plasma extracellular vesicles give new insights for monitoring and managing disease progression in prostate cancer patients
The study by Albino et al. is published in Communications Biology and is available at https://doi.org/10.1038/s42003-020-01642-5. The work is a collaborative effort involving many rese...
Second generation antibody protects from SARS-CoV-2, its variant and prevents it from mutating to resist therapy
The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation ‘double antibody’ that protects from ...
New Ebolavirus treatment sees the light thanks to basic research performed in Ticino
While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treatment against another well-known virus, much les...
Congratulations to Prof. Alimonti and his Molecular Oncology team on receiving the Prostate Cancer Foundation Challenge Award
Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this pres...
IOR researchers suggest that androgen-deprivation treatments for prostate cancer could protect men from COVID-19
The so-called “androgen-deprivation” treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated ...
